AOD 9604 had six human trials and 900 participants. Phase IIa showed positive results. Then the pivotal Phase IIb failed at every dose tested. Development was terminated in 2007. The trial history is AOD 9604: Peptide Claims vs Clinical Reality, AOD 9604 is marketed as a fat metabolism peptide derived from a growth hormone fragment, often positioned as HGH like without HGHs side effects. The AOD 9604: Peptide Claims vs Clinical Reality AOD 9604 is marketed as a fat metabolism peptide derived from a growth hormone fragment, often positioned as HGH like without HGH's side effects. The clinical question AOD 9604 Peptide Therapy in Dubai Targeted Fat Metabolism and Body Composition